OncoMatch/Clinical Trials/NCT04437160
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
Is NCT04437160 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Epirubicin or Pirarubicin and Cyclophosphamide for triple negative breast cancer.
Treatment: Epirubicin or Pirarubicin · Cyclophosphamide — This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative (ihc 0/1+ or ish non-amplified)
Required: ESR1 negative (< 10%)
Required: PR (PGR) negative (< 10%)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — neoadjuvant
Patient must have received platinum and taxanes neoadjuvant chemotherapy for at least 4 cycles and no tumor progression occurred.
Must have received: taxane — neoadjuvant
Patient must have received platinum and taxanes neoadjuvant chemotherapy for at least 4 cycles and no tumor progression occurred.
Cannot have received: anthracycline
Previous neoadjuvant chemotherapy with anthracycline or other drugs (except platinum and taxanes).
Cannot have received: other cytotoxic chemotherapy
Exception: except platinum and taxanes
Previous neoadjuvant chemotherapy with anthracycline or other drugs (except platinum and taxanes).
Cannot have received: platinum-based chemotherapy
Exception: alone
Previous neoadjuvant chemotherapy with platinum or taxanes alone.
Cannot have received: taxane
Exception: alone
Previous neoadjuvant chemotherapy with platinum or taxanes alone.
Cannot have received: adjuvant therapy
Patients have received other adjuvant therapy.
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Patients without severe kidney disease
Liver function
Patients without severe liver disease
Cardiac function
Patients without severe heart disease
Patients without severe heart, lung, liver and kidney disease. Adequate hematologic and end-organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify